Pharma giant Johnson & Johnson (NYSE: JNJ) hosted a review of its pharmaceutical businesses Wednesday, and analysts came away largely impressed.
Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with a $145 price target.
BMO Capital Markets analyst Joanne Wuensch reiterated an Outperform rating and $157 price target.
Morgan Stanley: J&J Story Looks Brighter
J&J expressed confidence in the acceleration of its pharma business in 2020, with the segment likely to see above-market growth through 2023, Lewis said in a Thursday note.
The analyst models about 7-percent growth for the segment in 2020, up from 4-percent growth in 2019.
The acceleration is premised Johnson & Johnson emerging from 2019 headwinds, increased pipeline contributions, indication expansion for current blockbuster franchises and the absence of any major patent/exclusivity expirations in the near-term, Lewis said.
"2019 could see a near perfect storm of Pharma headwinds but moving past these, acceleration is likely and could drive stock performance," the analyst said.
J&J expects at least 10 new blockbuster approvals and filings from 2019-2023 — including the recently launched Spravato and Balversa — and 10 potential 2019-2023 filings, according to Morgan Stanley.
"In addition to this, the company highlighted at least 40 line extensions for current franchises, including over 10 with $500mn potential," Lewis said.
Morgan Stanley expects consensus estimates to move higher for the stock.
BMO: J&J Continues To Innovate
J&J's discipline to acquire and divest assets in its health care portfolio, its pristine balance sheet and its high dividend yield make the stock a strong defensive choice, Wuensch said in a Wednesday note.
The following are the analyst's key takeaways from the event:
• Stelara is the company's largest asset, contributing in the psoriasis and Crohn's disease markets.
• Tremfya, a selective IL 23 inhibitor for psoriasis, is delivering more than $500 million in global sales in its first year.
• Darzalex is redefining multiple myeloma treatment, including combo therapies.
• Imbruvica is defining a new standard-of-care in chronic lymphocytic leukemia.
• J&J is leveraging its Actelion acquisition for pulmonary hypertension management.
• The recently approved Spravato has a vast market opportunity in treatment-resistant depression.
"Despite the concerns of pricing pressure and generic and biologic competition, J&J continues to do what it does best, innovate," Wuensch said.
The Price Action
J&J shares, which have gained roughly 7 percent year-to-date, were trading up 1.04 percent at $138.31 at the time of publication Thursday.
Related Link: Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
Photo courtesy of Johnson & Johnson.
Latest Ratings for JNJ
View More Analyst Ratings for JNJ
View the Latest Analyst Ratings
See more from Benzinga
- Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
- The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
- Vistagen Shares Fall Under After Depression Drug Flunks Midstage Trial
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.